Nasdaq to Delist Windtree Therapeutics for Minimum Bid Price Noncompliance

Reading Time: < 1 minute

Nasdaq has notified Windtree Therapeutics (WINT) that it will delist the company’s stock for failing to maintain a minimum bid price of $1.00 per share, as required by Nasdaq Listing Rule 5550(a)(2).

Trading will be suspended at the open on August 21, 2025. The company confirmed the notification in an SEC filing on Wednesday.

Windtree’s stock has plummeted over 99% this year and closed at just $0.11, following a pattern seen recently with other delisted firms like bitcoin miner Argo Blockchain.